spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Everolimus 

 HSMN NewsFeed - 1 Oct 2021
Breckenridge Announces Launch of its 10mg strength for Everolimus Tablets (generic for Afinitor(R))
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 13 Jul 2020
SINOMED(R) Completes One-Year Follow-Up of the PIONEER-III European, US and Japanese Trial of the BuMA Supreme(R) Coronary Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Sep 2019
OrbusNeich(R) Announces Japan Approval for COMBO(R) Plus Coronary Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 18 Sep 2019
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2018
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2017
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1]
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2017
Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2016
InspireMD Names Dr. James Barry as President and CEO
Devices Interventional Personnel
 HSMN NewsFeed - 13 May 2016
Boston Scientific Announces Schedule of Presentations at EuroPCR 2016
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2016
Abbott's Absorb(TM), the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 15 Jul 2014
InspireMD Appoints Dr. James Barry as Chief Operating Officer
Devices Interventional Personnel
 HSMN NewsFeed - 21 May 2014
Boston Scientific Reports Strong Performance Data For SYNERGY(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 1 May 2014
Boston Scientific Launches Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Dec 2013
Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2013
Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 22 May 2013
Boston Scientific Promus PREMIER(TM) and SYNERGY(TM) Drug-Eluting Stent Systems Provide Exceptional Safety and Efficacy Data
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2013
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 May 2013
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2013
Abbott Initiates Clinical Trial of Absorb(TM) in the United States
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Nov 2012
First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY(TM) Coronary Stent System Featuring a Bioabsorbable Polymer Coating
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 Oct 2012
Boston Scientific Receives CE Mark Approval for the SYNERGY(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 24 Oct 2012
PROMUS Element(TM) and PROMUS Element(TM) Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 23 Oct 2012
The Boston Scientific PROMUS Element(TM) Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Oct 2012
OrbusNeich's COMBO Dual Therapy Stent(TM) to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 4 Jun 2012
Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element(TM) Plus Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 18 May 2012
PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 10 May 2012
Boston Scientific Announces Schedule For EuroPCR 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 22 Mar 2012
OrbusNeich's Genous(TM) Technology Effectively Promotes Endothelialization and Reduces Thrombogenicity
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Mar 2012
Boston Scientific Announces Launch of PROMUS Element(TM) Platinum Chromium Stent System in Japan
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2012
Boston Scientific Announces First Implant and Market Launch of PROMUS Element(TM) Plus Stent System in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Jan 2012
Boston Scientific Announces Favorable Ruling in Patent Infringement Case
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 22 Dec 2011
Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease
Devices Interventional
 HSMN NewsFeed - 8 Dec 2011
Abbott Initiates Clinical Trial to Evaluate the Absorb(TM) Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Nov 2011
Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 1 Nov 2011
Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2011
Boston Scientific Launches Promus Element™ Stent System In China
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Oct 2011
Boston Scientific Begins Clinical Trial Enrollment for OMEGA(TM) Platinum Chromium Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Sep 2011
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
Devices
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2011
Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 25 May 2011
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS(R) 2.25 mm Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2011
PROMUS Element Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Apr 2011
Boston Scientific Announces FDA Approval and U.S. Launch of ION Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Apr 2011
Boston Scientific's Promus Element Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Workhorse Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Mar 2011
Boston Scientific Announces European Approval and Launch of OMEGA Platinum Chromium Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Feb 2011
Boston Scientific Launches PROMUS(R) Element and TAXUS(R) Element Stent Systems in India
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2011
Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Jan 2011
Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY Drug-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2010
Abbott's Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Sep 2010
Boston Scientific's TAXUS(R) Element Stent Demonstrates Strong Outcomes in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2010
PROMUS(R) Element Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 3 Aug 2010
Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jun 2010
Boston Scientific Announces European Launch and First Implants of Platinum Chromium TAXUS(R) Element Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2010
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 25 May 2010
Abbott's Groundbreaking Bioresorbable Technology Continues to Demonstrate Exceptional Clinical Results
Devices Interventional Cardiology
 HSMN NewsFeed - 25 May 2010
Medtronic's Resolute(R) Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2010
Boston Scientific Announces Schedule for EuroPCR 2010
Devices Interventional Cardiology
 HSMN NewsFeed - 12 May 2010
Boston Scientific Announces European Approval of Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2010
Boston Scientific Completes Enrollment in PLATINUM Trials for Small Vessels and Long Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2010
Boston Scientific Settles Longstanding Patent Disputes With J&J
Devices Litigation Interventional Cardiology
 HSMN NewsFeed - 20 Jan 2010
Court Finds J&J Patents Invalid
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 8 Jan 2010
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 2 Nov 2009
Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Sep 2009
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Jul 2009
FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 23 Jun 2009
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2009
Boston Scientific Announces Schedule for EuroPCR 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2009
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Devices Interventional
 HSMN NewsFeed - 26 Mar 2009
Boston Scientific Announces Schedule For ACC 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2009
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Mar 2009
Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Feb 2009
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Feb 2009
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Jan 2009
Boston Scientific Acquires Labcoat Limited
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Oct 2008
Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2008
Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 8 Oct 2008
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 2 Jun 2008
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 12 May 2008
Medtronic Announces Start of International Study Comparing Endeavor(R) Resolute Drug-Eluting Stent to Abbott's Xience(R) V
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Apr 2008
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
SPIRIT II Explores Long-Term Performance of XIENCE V Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Mar 2008
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2008
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
Devices Reimbursement Interventional Cardiology
 HSMN NewsFeed - 29 Nov 2007
Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Nov 2007
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Nov 2007
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Nov 2007
Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 22 Oct 2007
Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Jul 2007
Boston Scientific Announces First Implant of TAXUS(R) Element(TM) Platinum Chromium Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Jul 2007
Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2007
Abbott Initiates First Clinical Study of Everolimus Eluting Stent System for Patients with Peripheral Arterial Disease
Devices Interventional
 HSMN NewsFeed - 22 May 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2007
Boston Scientific Announces Schedule for EuroPcr 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Spirit III Clinical Trial Demonstrates Positive Performance for Both TAXUS(R) and PROMUS(TM) Drug-Eluting Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Boston Scientific Announces Schedule for ACC 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Feb 2007
Abbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2006
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2006
Data in Complex Patients and Lesions from OLYMPIA Registry Support Safety and Efficacy of TAXUS(R) Liberte(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Oct 2006
Abbott Reports Initial Results From World's First Clinical Trial Featuring a Fully Bioabsorbable Drug-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Oct 2006
Boston Scientific to Highlight Broad Range of Clinical Trial Results Reinforcing Safety and Efficacy of TAXUS(R) Coronary Stent Systems at TCT 2006
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2006
Abbott to Present New Data Across Its Vascular Portfolio at TCT 2006
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Oct 2006
Boston Scientific Becomes only Company with Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 3 Oct 2006
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Sep 2006
Abbott Announces Continued Expansion of Vascular Operations in Ireland to Prepare for Drug Eluting Stent Manufacturing
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 46

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 46 additional stories matching:
Everolimus
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.